An Assessment of Intralesional Epidermal Growth Factor for Treating Diabetic Foot Wounds
Open Access
- 1 January 2017
- journal article
- Published by MDPI AG in Journal of the American Podiatric Medical Association
- Vol. 107 (1) , 17-29
Abstract
Background: Intralesional epidermal growth factor (EGF) has been available as a medication in Turkey since 2012. We present the results of our experience using intralesional EGF in Turkey for patients with diabetic foot wounds. Methods: A total of 174 patients from 25 Turkish medical centers were evaluated for this retrospective study. We recorded the data on enrolled individuals on custom-designed patient follow-up forms. Patients received intralesional injections of 75 μg of EGF three times per week and were monitored daily for adverse reactions to treatment. Patients were followed up for varying periods after termination of EGF treatments. Results: Median treatment duration was 4 weeks, and median frequency of EGF administration was 12 doses. Complete response (granulation tissue >75% or wound closure) was observed in 116 patients (66.7%). Wounds closed with only EGF administration in 81 patients (46.6%) and in conjunction with various surgical interventions after EGF administration in 65 patients (37.3%). Overall, 146 of the wounds (83.9%) were closed at the end of therapy. Five patients (2.9%) required major amputation. Adverse effects were reported in 97 patients (55.7%). Conclusions: In patients with diabetic foot ulcer who received standard care, additional intralesional EGF application after infection control provided high healing rates with low amputation rates.Keywords
This publication has 24 references indexed in Scilit:
- Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcersBMC Pharmacology and Toxicology, 2013
- Granulation Response and Partial Wound Closure Predict Healing in Clinical Trials on Advanced Diabetes Foot Ulcers Treated With Recombinant Human Epidermal Growth FactorDiabetes Care, 2013
- Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closureInternational Wound Journal, 2009
- Long-Term Outcome and Disability of Diabetic Patients Hospitalized for Diabetic Foot UlcersDiabetes Care, 2008
- Guest Editorial: are diabetes‐related wounds and amputations worse than cancer?International Wound Journal, 2007
- Intralesional injections of Citoprot‐P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputationInternational Wound Journal, 2007
- Diagnosis and Treatment of Diabetic Foot InfectionsClinical Infectious Diseases, 2004
- Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studiesDiabetes/Metabolism Research and Reviews, 2004
- Human Epidermal Growth Factor Enhances Healing of Diabetic Foot UlcersDiabetes Care, 2003
- Epidermal growth factor and keratinocyte growth factor differentially regulate epidermal migration, growth, and differentiationWound Repair and Regeneration, 2000